Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Alphamab Oncology, Nanolek Partner on Armocibart Hemophilia Prophylaxis for Russian and EAEU Markets

Fineline Cube Jul 7, 2026
Company Deals

TrueLab Biopharmaceutical, Bionyra Pharma Forge $985M TL1A Antibody Deal with Dual IBD Candidates

Fineline Cube Jul 7, 2026
Company Deals

cAMPfield Therapeutics Launches with $180M Series A to Advance Prifemilast PDE4 Inhibitor for IBD

Fineline Cube Jul 7, 2026
Company Deals

BriSTAR Immunotech Secures $28M Series C to Advance STAR-T Platform and In Vivo Technology

Fineline Cube Jul 7, 2026
Company Deals

Formosa Pharmaceuticals, Samil Pharma Expand Partnership with APP13007 Vietnam Licensing Deal

Fineline Cube Jul 7, 2026
Policy / Regulatory

Guangdong Launches “Spring Rain Action” to Accelerate Medical Device Innovation Transformation with 900+ Clinical Achievements Target

Fineline Cube Jul 7, 2026
Company Drug

Sino Biopharmaceutical Submits China Marketing Application for World’s First Intra-Incisional Long-Acting Ropivacaine Analgesic

Fineline Cube Jul 6, 2026
Company Drug

Shaanxi Micot Enrolls First Patient in Phase Ib/II Clinical Trial of MT1002 for Acute Ischemic Stroke Treatment

Fineline Cube Jul 6, 2026
Company

CanSino Biologics Reports 2023 Revenue Dip Amid Reduced COVID-19 Vaccine Demand

Fineline Cube Mar 28, 2024

CanSino Biologics (HKG: 6185), a leading Chinese biopharmaceutical company, has released its financial report for...

Company Deals

Recbio and Rongsheng Biotech Join Forces to Develop New Adjuvant Vaccine Technologies

Fineline Cube Mar 28, 2024

Jiangsu Recbio Technology Co., Ltd (HKG: 2179) and Shanghai Rongsheng Biotech Co., Ltd have announced...

Medical Device R&D

Tianjin University Team Develops Self-Sustaining Na-O2 Battery for Implantable Devices

Fineline Cube Mar 28, 2024

Researchers at China’s Tianjin University of Technology have made a groundbreaking advancement with the development...

Company Drug

Zai Lab and Novocure Report Positive Phase III Results for TTFields in NSCLC Brain Metastases

Fineline Cube Mar 28, 2024

Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688), a biopharmaceutical company based in China, and Novocure...

Company Deals

Merck Expands Global Footprint with Largest M Lab Collaboration Center in Shanghai

Fineline Cube Mar 27, 2024

Merck KGaA (ETR: MRK), a leading German technology company, has announced the completion of the...

Company Deals

Kangtai Biological Partners with AstraZeneca and Beijing Daxing District to Boost Vaccine Market Presence

Fineline Cube Mar 27, 2024

Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a prominent biopharmaceutical company based in China,...

Company Drug

Jiangsu Hengrui Receives NMPA Approval for SHR-7631 ADC Clinical Study in Solid Tumors

Fineline Cube Mar 27, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...

Company Drug

Wuhan YZY Biopharma Initiates Phase II Study for M701 in Malignant Pleural Effusion Treatment

Fineline Cube Mar 27, 2024

Wuhan YZY Biopharma Co., Ltd (HKG: 2496), a biopharmaceutical company based in China, has announced...

Company Medical Device

Acotec Scientific Receives NMPA Approval for Innovative Cardiovascular Devices

Fineline Cube Mar 27, 2024

Acotec Scientific Holdings Ltd (HKG: 6669), a leading medical device company based in China, has...

Company

Sanofi Launches KiDS Program in China to Boost Health Literacy in Schools

Fineline Cube Mar 27, 2024

Olivier Charmeil, Executive Vice-President for General Medicines at France-based Sanofi S.A. (NASDAQ: SNY), visited China...

Company

WuXi Bio Reports 2023 Revenue Growth Amid COVID-19 Business Loss and Geopolitical Tensions

Fineline Cube Mar 27, 2024

WuXi Bio (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) based in...

Company Drug

Innovent Biologics Initiates Phase III Neoshot Study for MSI-H/dMMR Colon Cancer Treatment

Fineline Cube Mar 27, 2024

Innovent Biologics, Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced the...

Company Drug

Alexion’s Ultomiris Secures FDA Approval for Anti-AQP4 Positive NMOSD Treatment

Fineline Cube Mar 27, 2024

AstraZeneca’s (AZ; NASDAQ: AZN) rare disease unit, Alexion, has registered its biologic Ultomiris (ravulizumab) with...

Policy / Regulatory

NMPA Mandates Electronic Permits for Anesthetic Drugs and Psychotropic Substances

Fineline Cube Mar 27, 2024

The National Medical Products Administration (NMPA) has issued a new notification aimed at enhancing the...

Company

Shanghai Fosun Pharma Reports 2023 Revenues, Highlights Innovation and R&D Progress

Fineline Cube Mar 27, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based...

Company Deals

AbbVie Acquires Landos Biopharma to Boost Autoimmune Disease Pipeline

Fineline Cube Mar 27, 2024

AbbVie (NYSE: ABBV) has announced its acquisition of Landos Biopharma (NASDAQ: LABP), a biopharmaceutical company...

Policy / Regulatory

National Drug Sampling Inspection Report Reveals High Compliance Rates in 2023

Fineline Cube Mar 27, 2024

The National Institute for Food and Drug Control (NIFDC) has released its “National Drug Sampling...

Company Drug

MSD’s Winrevair Approved by FDA as First Activin Signaling Inhibitor for Pulmonary Arterial Hypertension

Fineline Cube Mar 27, 2024

The US Food and Drug Administration (FDA) has granted Merck, Sharp & Dohme (MSD; NYSE:...

Policy / Regulatory

China’s National Adverse Drug Reaction Report for 2023 Highlights Stability in Reporting Trends

Fineline Cube Mar 27, 2024

The National Center for ADR Monitoring has released its “National Adverse Drug Reaction Monitoring Annual...

Company

Lee’s Pharmaceutical Holdings Ltd Reports 2023 Financials with Focus Shift to Patented and Generic Drugs

Fineline Cube Mar 27, 2024

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), a leading pharmaceutical company based in China, has released...

Posts pagination

1 … 408 409 410 … 691

Recent updates

  • Alphamab Oncology, Nanolek Partner on Armocibart Hemophilia Prophylaxis for Russian and EAEU Markets
  • TrueLab Biopharmaceutical, Bionyra Pharma Forge $985M TL1A Antibody Deal with Dual IBD Candidates
  • Shanghai ZJ Bio-Tech Ebola Detection Kit Receives WHO Emergency Use Listing for Bundibugyo Strain
  • cAMPfield Therapeutics Launches with $180M Series A to Advance Prifemilast PDE4 Inhibitor for IBD
  • BriSTAR Immunotech Secures $28M Series C to Advance STAR-T Platform and In Vivo Technology
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Alphamab Oncology, Nanolek Partner on Armocibart Hemophilia Prophylaxis for Russian and EAEU Markets

Company Deals

TrueLab Biopharmaceutical, Bionyra Pharma Forge $985M TL1A Antibody Deal with Dual IBD Candidates

Company Medical Device

Shanghai ZJ Bio-Tech Ebola Detection Kit Receives WHO Emergency Use Listing for Bundibugyo Strain

Company Deals

cAMPfield Therapeutics Launches with $180M Series A to Advance Prifemilast PDE4 Inhibitor for IBD

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.